Heavy-Atom-Free Photosensitizers: From Molecular Design to Applications in the Photodynamic Therapy of Cancer,Accounts of Chemical Research

当前位置： X-MOL 学术 › Acc. Chem. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Heavy-Atom-Free Photosensitizers: From Molecular Design to Applications in the Photodynamic Therapy of Cancer
Accounts of Chemical Research ( IF 16.4 ) Pub Date : 2020-12-08 , DOI: 10.1021/acs.accounts.0c00606
Van-Nghia Nguyen _{1,

2} , Yuxin Yan ₃ , Jianzhang Zhao ₃ , Juyoung Yoon ₁

Affiliation

Photodynamic therapy (PDT) is a clinically approved therapeutic modality that has shown great potential for the treatment of cancers owing to its excellent spatiotemporal selectivity and inherently noninvasive nature. However, PDT has not reached its full potential, partly due to the lack of ideal photosensitizers. A common molecular design strategy for effective photosensitizers is to incorporate heavy atoms into photosensitizer structures, causing concerns about elevated dark toxicity, short triplet-state lifetimes, poor photostability, and the potentially high cost of heavy metals. To address these drawbacks, a significant advance has been devoted to developing advanced smart photosensitizers without the use of heavy atoms to better fit the clinical requirements of PDT. Over the past few years, heavy-atom-free nonporphyrinoid photosensitizers have emerged as an innovative alternative class of PSs due to their superior photophysical and photochemical properties and lower expense. Heavy-atom-free nonporphyrinoid photosensitizers have been widely explored for PDT purposes and have shown great potential for clinical oncologic applications. Although many review articles about heavy-atom-free photosensitizers based on porphyrinoid structure have been published, no specific review articles have yet focused on the heavy-atom-free nonporphyrinoid photosensitizers.

中文翻译：

重原子无光敏剂：从分子设计到癌症光动力疗法中的应用

光动力疗法（PDT）是一种临床批准的治疗方式，由于其出色的时空选择性和固有的非侵入性性质，已显示出治疗癌症的巨大潜力。但是，PDT尚未充分发挥其潜力，部分原因是缺少理想的光敏剂。有效的光敏剂的常见分子设计策略是将重原子掺入光敏剂结构，引起人们对暗毒性提高，三重态寿命短，光稳定性差以及重金属潜在高昂成本的担忧。为了解决这些缺点，已经致力于开发先进的智能光敏剂而不使用重原子来更好地满足PDT的临床要求，取得了重大进展。在过去的几年中，由于无重原子非卟啉类光敏剂具有优异的光物理和光化学性能，且费用较低，因此已成为PS的创新替代类。不含重原子的非卟啉类光敏剂已广泛用于PDT，并且在临床肿瘤学应用中显示出巨大潜力。尽管已经发表了许多有关基于卟啉类结构的无重原子的光敏剂的评论文章，但尚无具体的评论文章集中于不含重原子的非卟啉类光敏剂。不含重原子的非卟啉类光敏剂已广泛用于PDT，并且在临床肿瘤学应用中显示出巨大潜力。尽管已经发表了许多有关基于卟啉类结构的无重原子的光敏剂的评论文章，但尚无具体的评论文章集中于不含重原子的非卟啉类光敏剂。不含重原子的非卟啉类光敏剂已广泛用于PDT，并且在临床肿瘤学应用中显示出巨大潜力。尽管已经发表了许多有关基于卟啉类结构的无重原子的光敏剂的评论文章，但尚无具体的评论文章集中于不含重原子的非卟啉类光敏剂。

更新日期：2021-01-05

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11